{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
telotristat ethyl
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Dexsotalol is an isomer of antiarrhythmic drug d,l-sotalol, but in opposite to drug, it increases the incidence of arrhythmias
Status:
Investigational
Source:
NCT01770548: Not Applicable Interventional Completed Autism
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
J Neurol Neurosurg Psychiatry. Oct 1981;44(10):932-4.: Not Applicable Human clinical trial Completed Tremor
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04649216: Phase 1 Interventional Completed Healthy Volunteers
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Chugai Pharmaceutical is developing a parathyroid 1 receptor agonist called as PCO371. It is known that parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor. PCO371 can provide a new treatment option for PTH-related disorders, including hypoparathyroidism. This drug participated in phase I clinical trial in healthy volunteers. However, Chugai Pharmaceutical has terminated this study. No recent reports of the development of PCO371are available.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Icopezil (previously known as CP-118,954) was developed as a selective acetylcholinesterase inhibitor for the treatment of cognitive disorders. Phase II trials of icopezil were underway in Japan and in the USA for the treatment of patients with Alzheimer's disease. However, Pfizer has discontinued these studies.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Vintriptol, a tryptophan ester of vinblastine, was developed as an antitumor drug. Vintriptol participated in a phase I clinical trial for the treatment of non-small cell lung cancer. As a result, was found a recommended dose for stage II. However, the further development of vintriptol was discontinued.
Status:
Investigational
Source:
NCT03594058: Phase 2 Interventional Completed Overactive Bladder
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Solabegron (GW427353), a beta-3 adrenoceptor agonist, is in development with AltheRx (now Velicept Therapeutics) for the treatment of irritable bowel syndrome (IBS) and overactive bladder (OAB). Solabegron was discovered and first developed by GlaxoSmithKline. It was acquired by AltheRx, which merged with Velicept in 2015 to continue development of the program. Solabegron has been tested in over 800 study subjects in a twice-a-day formulation and demonstrated efficacy in the treatment of OAB as well as IBS. A once daily formulation designed to optimize patient convenience as well as efficacy has been developed and is currently being evaluated in a phase 2b dose ranging clinical trial. A Phase 2b dose ranging study with the twice daily formulation also began enrollment in Q1 2018.
Class (Stereo):
CHEMICAL (ACHIRAL)
LEDOXANTRONE, a benzothiopyranoindazole, is an intercalating agent. Its mechanism of action is probably due to DNA helicase blockade. It was under development for the treatment of prostate and ovarian cancers.
Status:
Investigational
Source:
INN:solypertine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Solypertine (WIN-18413-2) is an antiadrenergic drug. Solypertine selectively blocked the conditioned avoidance response in rats. Solypertine potentiated hexobarbitone sleeping time, caused hypothermia and afforded protection from amphetamine toxicity inaggregated mice.
Class (Stereo):
CHEMICAL (ACHIRAL)
Risotilide is a Class III antiarrhythmic agent that inhibits the voltage-dependent potassium channel. Risotilide prolongs cardiac action potentials and refractory periods. It was shown to reduce ventricular vulnerability in a study on arrhythmogenic effects of left ventricular hypertrophy (LVH) in the intact heart in cats. Phase I and II trials have been conducted, but development of this drug has been discontinued.
